Furthermore, it is also being studied in the treatment of cancers that specifically occur in the activated B cell subtype of diffuse large B cell lymphoma (ABC-DLBCL) patient populations with the MyD88 L265P mutation [18,19]. Here, MYD88 is linked to diffuse large B-cell lymphoma.